# BeiGene

China’s Oncology Vanguard: Biotech Innovations Take Center Stage at ASCO 2026

Chinese biotech firms and researchers have achieved a record-breaking presence at the 2026 ASCO Annual Meeting, with 95 abstracts selected for major sessions. Led by STAR Market innovators like BeiGene and Biokin, this surge reflects China's transition from a generic-drug manufacturer to a global leader in high-impact oncology research.

NeTe2026年5月26日 16:38

#ASCO 2026#Oncology#Biotechnology

Close-up of a German 'Einfahrt' sign on a textured wall with ivy, conveying an entryway directive.

Health

A Bitter Pill: Trump’s 100% Drug Tariffs and the Future of Chinese Biotech

President Trump has signed an executive order under Section 232 to impose 100% tariffs on imported patent drugs and APIs, aimed at forcing price concessions and manufacturing onshoring. While Chinese biotech firms face new challenges, many are already pivoting toward U.S.-based production to mitigate these trade risks.

SoBiz2026年4月4日 05:28

#Trump#Tariffs#Biotechnology